Artificial skin breakthrough for Melbourne patient
In a first-of-its-kind adult case, a Melbourne man has had his burns repaired with bioengineered skin, decreasing his need for skin grafting and significantly reducing his risk of deadly infection.
Specialists and researchers at The Alfred and Monash University have taken a major step forward in the quest to reach the ‘holy grail’ of burns treatment, with a patient’s extensive full-thickness burns successfully treated with new skin grown from his own skin cells in an Alfred-based laboratory.
Designed to treat life-threatening burns, experts hope the breakthrough, over 10 years in the making, will significantly improve outcomes for patients, and eventually replace the need to use traditional donor sites for healing patients with extensive severe burns, said reconstructive plastic surgeon at The Alfred, A/Prof Heather Cleland.
“Almost half of burns survivors live with pain and disability caused by scarring and infection, made worse by the need to use traditional skin grafts,” A/Prof Cleland said.
“With this technique, we are cultivating skin that is a practical and safe and which, by eliminating the need for grafting using the patient’s unburnt skin for donor sites, will significantly improve the outcomes for patients with very serious burns.”
The technique also has the potential to significantly reduce long-term scarring, which can be associated with itching and pain, and sometimes loss of function, said Group Leader at the Skin Bioengineering Laboratory, A/Prof Shiva Akbarzadeh.
“We isolate and expand patients’ own skin cells and allow them to form new skin, and from skin cell harvest, it takes approximately four weeks to grow the mature skin ready for grafting,” A/Prof Akbarzadeh said.
“By harnessing the body’s natural wound repair mechanisms, we expect little scarring of the treated sites long term.”
The trial, a partnership between The Alfred and Monash University, is the result of collaborative research between skin cell biologists and reconstructive plastic surgeons, said A/Prof Akbarzadeh.
“Every step of the way has been developed based on what we’ve learnt from our previous clinical trials and feedback from the treating surgeons and patients,” A/Prof Akbarzadeh said.
This trial is funded through the Medical Research Future Fund.
